FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> United Kingdom

British biotech execs sour on industry’s 'dire' shape

Investors have sourced on publicly traded biotech companies in a big way. IPOs appear to be a less and less appealing way to cash out venture players. And don't look for any kind of a change near-term.

That bleak message has just been repeated for readers of the Financial Times, who were treated to a series of negative assessments from some of the U.K.'s top biotech execs. Too many trial disappointments in too short a period of time has been fingered for much of the blame. 

One sample of the industry's view: "While there are some very strong companies developing--including Oxford BioMedica, Acambis and Protherics--the sector is really in dire shape," says Glyn Edwards, chief executive of Antisoma.

- read the article in the Financial Times

Related Articles:
Investor says biotech is languishing in the U.K.
Bleak market will slam European research efforts
European investors sour on biotech market
Biopharma execs sign on to tout UK's R&D work

More stories about United Kingdom  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 13 + 8?
To combat spam, please solve the math question above.